
Why CAR T May Belong Before Bispecifics in Multiple Myeloma
At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.
In an interview with Yan Leyfman, MD, a hematology-oncology fellow at the Meyer Cancer Center of NewYork-Presbyterian/Weill Cornell Medicine and a medical correspondent for CancerNetwork® at the 44th Annual Chemotherapy Foundation Symposium (CFS®), Ajai Chari, MD, discussed how clinicians should choose between chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies as both move into earlier lines of treatment for patients with multiple myeloma, and whether the order in which they are given affects outcomes.
Chari noted that both modalities have produced progression-free survival (PFS) and overall survival benefits and appear to work better when used earlier, when T cells may be more fit and disease burden lower. He described the pace of disease as a key deciding factor: patients with rapidly progressive or extramedullary disease may be better served by an off-the-shelf bispecific, whereas CAR T-cell therapy offers the longest treatment-free interval available to date. Because every B-cell maturation antigen (BCMA)–directed therapy appears to diminish the PFS achieved with the next, he argued that clinicians should consider giving CAR T-cell therapy first to get the most out of it, reserving other BCMA-targeted agents for later.
Chari is a professor of medicine at the University of California, San Francisco (UCSF).
Transcript:
Leyfman: As CAR T-cell therapies and bispecifics move into earlier lines of therapy, how should clinicians decide which patients benefit from which approach, and does the sequence matter for patient outcomes?
Chari: First, I think it is worth mentioning that both products have shown not only PFS benefits but overall survival benefits. Many of us in the myeloma community feel that this movement is really justified, because there is also a push in the community to save these for later, because that is where they were approved. But that assumes you do not have attrition—that the patients will be alive. And I think these products work better when used earlier. For example, bispecific monotherapy has a response rate of 60% to 70% in advanced myeloma; in newly diagnosed disease, monotherapy is 80%, and in smoldering myeloma, it is 95% to 100%. It is the same disease, but the T cells, we think, are better, and maybe the burden is lower.
Between the two [options], I think one of the main questions is the pace of disease. If it is rapidly progressive, particularly if it is extramedullary disease, by the time you control the myeloma, you may miss the opportunity to do the CAR T. So I think rapidly progressing patients should probably go more toward an off-the-shelf product like a bispecific.
On the other hand, CAR T-cell therapies clearly have the best treatment-free interval that we have to date, with ciltacabtagene autoleucel [cilta-cel; Carvykti] in particular. The PFS is 3 years in patients with advanced disease, and we think it is better in less heavily treated patients. The cure fraction is about a third of patients in the heavily treated setting, and now maybe 50% [when used earlier]. If you want to give patients that treatment-free interval, I think CAR T should come first.
A lot of this debate goes back to the IMWG [International Myeloma Working Group] consensus paper. We talked about why that is: at that time, there were cilta-cel data showing that the PFS of 3 years drops to 5 months with a prior bispecific, or 9 months with a prior ADC [antibody-drug conjugate]. Admittedly, those are older data sets, from when these products were given until progression. My pushback is that an ADC at that time was given for 3 to 4 months, so it is not as though you were beating patients up with years of therapy, and we do not think the ADC affected soluble BCMA, BCMA expression, or T cells. So why would it decrease efficacy?
If you now look at the entire data set, every BCMA therapy has adversely affected the PFS of the next therapy. That is true for bispecifics before or after CAR T, and for CAR T before or after bispecifics. When you touch BCMA once, it will probably give you anywhere from a 40% to 80% decrement in the next PFS. If you are going to go through the hassle of apheresis, manufacturing, CAR T infusion, and half a million dollars, why not get the best mileage out of that, do the CAR T first, and then use your other products later?
Related to this article








